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ABSTRACT
Endemic Burkitt lymphoma (eBL) is primarily a childhood cancer in parts of 
Africa and Brazil. Classic studies describe eBL as a homogeneous entity based on 
t(8;14) IgH-Myc translocation and clinical response to cytotoxic therapy. By contrast, 
sporadic BL (sBL) in Western countries is considered more heterogeneous, and 
affects both children and adults. It is overrepresented in AIDS patients. Unlike 
diffuse large B cell lymphoma (DLBCL), molecular subtypes within BL have not been 
well defined. We find that differential IgM positivity can be used to describe two 
subtypes of pediatric Burkitt lymphoma both in a high incidence region (Brazil), 
as well as in a sporadic region (US), suggesting the phenotype is not necessarily 
geographically isolated. Moreover, we find that IgM positivity also distinguishes 
between early and late onset BL in the standard Eµ-Myc mouse model of BL. This 
suggests that the t(8;14) translocation not only can take place before, but also after 
isotype switch recombination, and that IgM-negative, t(8;14) positive lymphomas 
in children should nevertheless be considered BL.
INTRODUCTION
Burkitt lymphoma (BL) is an aggressive Non-
Hodgkin B cell lymphoma. Histologically, it exhibits a 
characteristic “starry-sky” appearance due to macrophages 
laden with phagocytized apoptotic debris within a 
background of malignant cells. Endemic BL (eBL) is 
the most common hematopoietic neoplasia of children 
in Sub-Saharan Africa. Denis Burkitt first described it 
in 1957 in Kampala, Uganda, and at the time, he noticed 
an association with Malaria; later, Epstein and Barr also 
identified the association with Epstein-Barr Virus (EBV) 
(reviewed in [1–3]). Endemic BL responds well to single 
agent cyclophosphamide (Cytoxan) or other relatively 
simple DNA damaging regimes (doxorubicin, vincristine), 
presumably because of its extremely rapid proliferation 
rate as ascertained by a Ki-67 index above 95%. eBL is 
considered to have a very homogenous immunophenotype 
with few secondary genomic aberrations [4, 5], perhaps 
because EBV activates oncogenic signaling pathways, 
which in EBV-negative BL are activated by driver 
mutations. There is a paucity of well-controlled clinical 
and molecular studies in regions that are endemic for BL, 
such as Sub-Saharan Africa.
Sporadic BL (sBL) is a very different disease in 
Western countries, and its immunophenotype is much 
more variable. In the 1990s, a subtype of sBL was 
recognized in HIV+ patients in the US and Europe 
(reviewed in [6]). Both forms of sBL in HIV+ and HIV- 
patients are equally proliferative and aggressive, but much 
more chemoresistant than eBL. In HIV- patients, sBL is 
seldom EBV-associated, with the exception of Brazilian 
cohorts that have an EBV expression intermediate between 
sBL and eBL [7]. HIV is now epidemic in the same 
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regions in which there is eBL; therefore, it is unclear if the 
classical histological diagnosis and established treatment 
options still hold.
There also exists the risk of misdiagnosis of BL and 
aggressive B-cell lymphoma with intermediate features 
between BL and diffuse large B cell lymphoma (DLBCL) 
[8]. Overexpression of the proto-oncogene c-Myc is 
the key molecular driver of BL. The t(8;14)(q24q32) 
translocation involving the IgH locus is considered 
a hallmark of eBL and sBL alike [9], though other 
translocations, t(2;8) or t(8;22), have been described, as 
well as cases of Myc activation by somatic mutation [10]. 
Indeed, Myc activation has been shown to occur in many 
lymphomas, e.g. those with plasmablastic morphology 
[11], motivating our search for additional markers to 
distinguish BL from high-grade DLBCL and to discern 
sub-types of BL. 
BL is considered a B cell tumor of germinal 
center (GC) or post-germinal center origin with a “sky-
high” proliferation rate akin to the staggering rate of 
centroblast proliferation in the dark zone of the GC. Prior 
to activation, mature B cells express IgM in a monomeric 
form on their cell surface, along with IgD. After activation, 
B cells undergo clonal expansion and class switch 
recombination (CSR), whereupon IgM is downregulated 
and IgG isotypes are expressed with a different constant 
region, while maintaining the same variable region. 
Clonal expansion takes place in the dark zone of the 
GC, as does IgG hypermutation and CSR. Subsequently, 
affinity maturation takes place in centrocytes within the 
less proliferative, light zone of the GC. Low affinity B 
cells die by apoptosis, whereas high affinity B cells circle 
back into the dark zone. We were interested in studying 
IgM expression in pediatric BL, since it allows for the 
distinction between BL originating in the dark zone of the 
GC, i.e. before CSR, and BL originating in light zone of 
the GC, i.e. after CSR. 
Here, we report IgM expression as a novel 
histological marker that distinguishes two subtypes 
of pediatric t(8;14) BL. Samples were obtained from 
patients in a sporadic setting (USA), and a high incidence, 
sporadic-like setting (Brazil). We chose to focus on 
pediatric patients because they are most likely to have 
causative primary translocations compared to adult 
patients; in addition, future potential comparisons to eBL 
patients, a primarily pediatric population, will be possible. 
Notably, IgM expression also distinguished early and late 
onset lymphomas in the standard Eµ-Myc mouse model 
of BL [12–14]. This suggests that IgM may be useful as a 
new biomarker to stratify pediatric BL.
RESULTS
First, we evaluated five t(8;14) positive cases of 
pediatric sBL from the UNC clinic (Table 1). All cases 
exhibited the prototypical “starry-sky” histopathology, 
and all cases exhibited nuclear Ki-67 staining in > 95% of 
tumor cells. As positive control, we used an experimental 
primary effusion lymphoma (PEL) xenograft, which was 
equally Ki-67 positive, but did not show the prototypical, 
interspaced pattern of macrophages. We found sIgM 
staining to be immensely variable in the BL cases 
(Figure 1): the cases in panels A and C were IgM positive, 
whereas the cases in panels B and D were IgM negative. 
The image in panel E shows a higher magnification of 
the IgM-positive staining in panel A, and panel F shows 
a higher magnification of the IgM-weak staining in panel 
B. Clearly, IgM expression is variable among BL carrying 
the t(8;14) translocation. On the basis of histology, clinical 
features (pediatric, neck region) and Myc translocation, 
it seems highly unlikely that these cases represent 
misdiagnosed DLBCL or plasmablastic lymphoma (PBL). 
We interpret this data to establish the existence of two sub-
types of sBL: those who are sIgM positive (type A) and 
those who are sIgM negative (type B).
CD79a is covalently associated with the B cell 
receptor; it is also called Ig-α and it is essential for B cell 
receptor (BCR) signaling and surface expression of IgM 
[17]. We hypothesized that if sIgM were not expressed, 
CD79a would be absent as well. This was indeed the case 
(Figure 2). In IgM-positive, “type A” BL, CD79a staining 
was readily apparent (Figure 2, panel C, E), whereas in 
IgM-negative, “type B” BL, CD79a staining was absent in 
most cells and much reduced in intensity in the remaining 
IgM faint staining cells (Figure 2, panel D, F). Both cases 
had equivalent levels of Ki-67 positivity. We concluded 
that “type B” BL had downregulated BCR expression. 
Second, we used a tissue micro array (TMA) of 
cases of sBL from Brazil to independently confirm the 
presence of these two subtypes. The characteristics of the 
TMA were previously described [7]. The incidence and 
composition of BL in the Brazilian general population 
is primarily of the sporadic-type with a high proportion 
of pediatric cases and EBV prevalence intermediate 
between that of endemic and sporadic. All cases were 
studied by FISH for Myc translocation, and we selected 
only those sBL cases with unequivocal evidence of Myc 
translocation, i.e. FISH-MYC index ≥10% [16]. All 
cases were CD10pos, BCL6pos, PAX5pos, and exhibited a 
Ki-67 index > 95%. There were 13 total; 12 were from 
male and 1 from female patients. The median age was 23 
(95%CI: 15.7 ... 34.6). We stringently defined “positive” as 
a consensus score of “3,” the highest score. We defined 
“negative” as a consensus score of “1,” the lowest possible 
score considering we had no patient that scored “0.” We 
encountered 6 sIgMpos (46%), and 4 sIgMneg (30%) cases in 
this otherwise homogeneous collection (Figure 3). Three 
additional cases were homogenously sIgMpos but at lower 
levels. We conclude that also in this larger collection of 
sBL, the typical BL cases can be sub-divided into two 
types: “type A” with high level sIgM expression and “type 
B” with low level or no sIgM expression. Although we 
Oncotarget63506www.impactjournals.com/oncotarget
chose a 10% FISH-MYC index threshold in order to filter 
the results in the most clinically stringent manner possible, 
we realize it may be acceptable to use a threshold of 
2.19% as previously validated [7]. In doing so, the median 
age is reduced to 11 years with a sample size of 30. By 
further restricting to pediatric only, i.e. age 21 or younger, 
the median age is reduced to 5 years with a sample size of 
19 patients. With these criteria, we encountered 9 sIgMpos 
(47%), and 10 sIgMneg (53%), with low-intermediate 
expression (scores of “1” to “2” exclusive) included as 
sIgMneg. These results are similar to our original subset 
of high-FISH-MYC patients, showing that these two 
subtypes are also discernible in exclusively pediatric 
patient populations.
Third, we evaluated sIgM expression in a classic 
mouse model of BL. In 1985, Adams and Cory developed 
the first Myc-driven model for BL in mice [12, 13]. 
This model has been a workhorse for understanding the 
molecular biology of BL and interventions against this 
disease ever since. Eµ-Myc mice are immunocompetent 
and cooperate with Eµ-BCL2 mice in a model of double-
hit lymphoma [18]. Eµ-Myc mice develop lymphoma as 
Table 1: Individual UNC cases of pediatric BL
Ki-67a IgMb CD79a Site Age Sex Myc FISH
Karyotype
(NC, not complete) Stage BCL-6
3+ 3 1 abdominal 11 M t(8;14) NC Abdomen 
limited,
BM neg
NC
3+ 1 1 neck 6 M t(8;14) 46,XY,dup(1)
(q?21q?31),?del(6)
(q15q21),t(8;14)
(q24;q32)[13]/46,XY[7]
IV NC
3+ 2 2 neck 5 M t(8;14) NC Neck limited, 
BM neg
NC
3+ 2 2 neck 5 M t(8;14) NC IV NC
3+ 3 3 pelvic 14 F t(8;14) NC III Positive
a3+ refers to > 95% of cells staining with high intensity.
bThe numeric scores correspond with the following: 1 = low intensity, 2 = intermediate intensity, 3 = high intensity.
Displayed are relevant immunophenotypical and clinical data on pediatric BL patients at UNC hospital. All patients had > 95% 
Ki-67 index and t(8;14) translocations, with varying degrees of IgM/CD79a expression and tumor localization.
Figure 1: Variant IgM expression in BL. (A, B, C, D) 200× magnification of different BL cases stained for IgM. (A, C) BL: Dark 
NovaRED™ staining evident, tumor cells are strongly positive. (B, D) BL: Staining is mostly negative with scant peripheral IgM in weakly 
positive cells. (E) Example of high intensity stain from panel (A) at 400× demonstrates IgM is located at the cell periphery. (F) Example of 
low intensity stain from panel (B) at 400× shows a distinct lack of IgM positive cells in comparison.
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Figure 2: Representative immunophenotypes of type A and type B BL. (A, C, E) Sections from a single BL patient classified 
as “Type A.” (B, D, F) Sections from a second BL patient classified as “Type B.” (A, B) Ki-67: NovaRED staining is dark and prevalent in 
the nuclei of nearly all cells. (C) IgM staining is dark and concentrated on nearly all cell surfaces, with hematoxylin-counterstained nuclei 
visible. (D) IgM staining is moderate and scattered, with few cells staining darkly. (E) CD79a staining is dark and concentrated on the most 
of the cell surfaces (> 85%). (F) CD79a staining is weak, appearing on less than half of cell surfaces. All images at 200× magnification.
Figure 3: IgM expression on a TMA of Brazilian BL. (A) Representative tissue section with an intensity score of “0,” representing 
a negative stain. Hematoxylin counterstain in cell nuclei is visible. (B) Representative tissue section with an intensity score of “1,” 
representing weakly stained tissue. Isolated cells stain weakly with NovaRED. (C) Representative tissue section with an intensity score of 
“2,” representing intermediate intensity. There is a large population of heterogeneously stained cells. (D) Representative tissue section with 
an intensity score of “3,” representing heavily stained tissue. Most of the cells have dark staining that obscures the nucleus significantly. 
All images at 400× magnification.
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early as 2 months of age, and the majority dies within 
6 months. The initial studies reported a biphasic tumor 
incidence curve; this has been amply documented since, 
and we recapitulated this phenotype in our colony 
(Figure 4, panel C). The tumors exhibit the typical 
BL “starry-sky” appearance due to the presence of 
macrophages laden with phagocytized apoptotic cells, 
and > 95% of the cells stain positive for Ki-67 (Figure 4, 
panel A). At present, no one molecular difference between 
“early” and “late” onset lymphoma in the Eµ-Myc model 
has been reported. Therefore, we tested the hypothesis 
that sIgM expression differs between “early” and “late” 
onset lymphoma. Indeed, in the “early” lymphomas, 
IgM expression was absent except for isolated cells 
with intracellular (ic) IgM accumulation (Figure 4, 
panels D and E). By contrast, late onset tumors exhibited 
universal IgM positivity, the majority of which was 
surface associated (Figure 4, panels F and G). The tumors 
responded to single agent cyclophosphamide/Cytoxan 
(Figure 5, panels B, D, F), which reduced the proliferating 
B220-positive B cells. This allowed for the non-lymphoma 
T cells in the mouse spleen to begin to fill in the empty 
space. We conclude that sIgM positivity also distinguishes 
two subtypes of lymphoma in the Myc-driven mouse 
model of BL. 
DISCUSSION
BL is a disease of multiple clinical presentations. 
The lymphoma originally discovered by Denis Burkitt 
is a disease clustered in development (early age) and by 
geography (endemic regions in Africa and Latin America) 
(reviewed in [1]). It is driven by the t(8;14) translocation, 
associated with EBV, and has been termed endemic BL 
(eBL). eBL responds readily to cytotoxic treatment [19]. 
By contrast, sporadic BL (sBL) is a disease that includes 
older individuals as well as children, has no geographic 
preference and a varying degree of EBV association [2]. 
It is rare in adults by comparison to DLBCL, except in 
the context of HIV-induced immunodeficiency [6]. This 
biphasic age distribution and the signature histology of BL 
are recapitulated in the Eµ-Myc mouse model [12–14, 18]. 
Figure 4: Biphasic tumor incidence and IgM expression of “early” and “late” onset BL in Eµ-Myc mouse model. 
(A) Ki-67 stain shown at 400X magnification. (B) Reference stain with no primary antibody. Hematoxylin-counterstained nuclei are in 
blue. Image at 400X magnification. (C) Fraction of tumor-free mice at time after birth in the colony. Each gray dot represents one animal. 
The red line indicates fit by broken stick regression. Also shown are examples of early onset (D, E) and late onset (F, G) lymphomas in the 
Eµ-Myc mouse. IgM staining is dark and concentrated either intracellularly (ic) or on the surface (s). Hematoxylin-counterstained nuclei 
are in blue. (D, E, F, G) Images at 200× magnification.
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Molecular profiling studies have established a 
common signature for sBL that distinguishes it from other 
types of Myc-translocated and Myc-activated DLBCL 
[20–22], and have also provided evidence for subtypes 
within sBL, e.g. those with or without activating mutations 
in ID3. ID3 mutations were absent in eBL compared to 
sBL [21, 23, 24]. Thus far, “molecular sBL” signatures 
were primarily derived from sBL collected in Northern 
European or US locations and have not distinguished 
between pediatric or adult patients [25]. To arrive at the 
molecular expression signatures, sBL was defined as 
CD20+, BCL6+, CD10+, BCL2-, CD5-, Ki-67 ≥ 95% and 
IgH-Myc translocation [15, 16]. In the aforementioned 
profiling studies, 100% of “molecular sBL” carried a 
BCL6 translocation; yet, only 88% carried the classical 
IgH-Myc translocation [20]. The “molecular sBL” 
category included 36 cases of “atypical” sBL because of 
a non-prototypical immunophenotype, and ultimately led 
to a 58-gene signature. Dave et al. arrived at very similar 
molecular signatures [22], and again, the molecularly 
defined sBL class contained cases that were inconsistent 
with classification based on the immunophenotypical 
definition of BL and of PBL [11, 15, 16, 26]. This report 
provides evidence that there exist additional subtypes of 
t(8;14) sBL that can be distinguished on the basis of IgM 
and CD79a expression.
We investigated a set of pediatric BL, each carrying 
the t(8;14) translocation. We noted first in a case series 
of sBL from the Southern United States, and then in a 
validation set of sBL from Brazil, that about half of the 
cases stained positive for sIgM, and half did not. Because 
of the high proportion of these two subtypes, and because 
all stained equally well for other markers (Ki-67, CD10), 
it is unlikely that the differential IgM positivity was the 
result of technical variation. Differential IgM expression 
also correlated with early and late onset lymphoma in the 
Eµ-Myc transgenic mouse model of BL. Since all Eµ- Myc 
mice are genetically identical and BL development is 
extremely rapid, this suggests two different developmental 
pathways towards BL. In the first scenario, which is 
characterized by early onset in the mouse, BL development 
is not dependent on IgM signaling. In the second scenario, 
which is characterized by later onset in the mouse, the 
lymphoma cells express high levels of IgM consistent with 
a dependency on “tonic” BCR signaling [27]. The discovery 
of sIgM as a novel marker to subtype pediatric sBL provides 
a new approach to elucidate the biology of BL.
IgM expression can be interpreted in the context of 
the t(8;14) translocation and class switch recombination 
(CSR). The t(8;14) translocation juxtaposes Myc to the 
Eα enhancer, and 8q24 is fused to one of the switch 
regions (Figure 6, panel A). If CSR takes place before the 
Figure 5: Response to cyclophosphamide in the Eµ-Myc mouse. Mock-treated (A, C, E) or cyclophosphamide (CTX) treated 
BL (B, D, F) in an Eµ-Myc mouse. (A, B) H&E staining. (C, D) Ki-67 staining. (E, F) Murine B220 staining (analogous to human CD19). 
Hematoxylin-counterstained nuclei are in blue. All images at 200X magnification.
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translocation event, IgM expression would have ceased 
already as the Cµ exon was replaced by any of the Cγ/ Cα 
regions. During the translocation 8q24 replaces Cγ/Cα and 
no isotype is ever expressed. This would correspond to 
IgMneg BL. If CSR takes place after the translocation event, 
and if 8q24 is fused to one of the Cγ/Cα switch regions 
rather than the Cµ switch region, IgM expression would 
be retained (Figure 6, panel B). This would result in a very 
broad distribution of translocation points, which has been 
observed [28]. In either case, the Myc translocation to the 
3ʹ region and to Eα is identical. Thus, IgMpos and IgMneg 
t(8:14) BL give the same result in the Myc FISH assay. 
Indeed, Figure 6 is an oversimplification of the human 
heavy chain locus. Whole genome sequencing established 
(i) a large duplication of the Cγ/Cα region and (ii) a high 
frequency of polymorphisms made up of deletions in the 
human population [29]. This indicates genome instability, 
in addition to and irrespective of CSR events. If the Myc 
translocation event took place before CSR, it is at least 
theoretically possible that CSR can take place afterwards. 
This event is depicted as CSR’ in Figure 6, panel B. 
The result would again be an IgM-negative t(8;14) BL. 
There also exists the possibility that CSR takes place on 
the Myc-translocated fragment, which would bring Myc 
into even closer proximity to Eα [30]. Another important 
marker of the pre- or post- CSR origin of BL is somatic 
hypermutation. Presumably, somatic hypermutation takes 
place in the cell, cycling back and forth between the light 
zone and dark zone, and it is dependent on sIg expression. 
There is conclusive evidence for the presence of somatic 
hypermutation in IgMpos BL; however particularly in 
reports on eBL, the extent seems highly variable [31]%. 
This suggests that the t(8;14) translocation event can occur 
either before CSR or after CSR. 
In summary, IgM expression can distinguish 
between t(8;14) BL that originate before CSR in the 
GC (IgMpos) and those that originate later in B cell 
development, after CSR (IgMneg); or instances where 
the t(8;14) tumor cells were nevertheless competent to 
complete CSR. This establishes IgM as an additional tool 
to help identify the cell of origin of BL. We observed that 
IgM expression was paralleled by CD79a expression. 
CD79a has acquired point mutations in the ITAM 
motif for a significant (~ 20%) fraction of DLBCL, but 
none have been reported in BL [32]. The role of BCR 
signaling in lymphomagenesis is not trivial, since it 
can transmit activating “tonic,” or “chronic” signals, as 
well as inhibitory signals in response to Fcγ-RIII [27]. 
Since CD79a is a requisite mediator of BCR surface 
translocation and signaling [17], one can conclude that 
the IgMnegCD79aneg BL cells do not depend on positive, 
nor respond to inhibitory, BCR signaling events. One may 
speculate that converse is true as well, i.e. IgMposCD79apos 
BL still depend on BCR signaling via CD79a as well as 
Figure 6: Representative figure of possible CSR events. Model of t(8;14) events that can give rise to either sIgM-negative or sIgM-
positive BL, depending whether the event takes place post CSR (A) or pre-CSR (B).
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its downstream target Bruton’s tyrosine kinase (BTK). If 
so, adding BTK inhibitors like ibrutinib to the treatment 
regimen may increase efficacy in IgMposCD79apos BL.
MATERIALS AND METHODS
Case selection at UNC chapel hill
Cases were collected at UNC Cancer Hospital 
and characterized as BL by histology [15, 16]; in short: 
the tumors showed cohesive growth of monotonous, 
intermediate-sized abnormal lymphoid cells with 
immunohistochemical expression of CD10 and CD20, and a 
high Ki-67 index (> 95%). Tdt and Bcl-2 were negative by 
immunohistochemistry. BCL-6 data was only available for 
one patient, which was positive. t(8;14) Myc rearrangement 
was ascertained by FISH studies. IgM stain intensity 
was quantified on a scale of 0–3, with 0 as negative, 1 as 
weak staining, 2 as intermediate, and 3 as strong staining. 
Intensity score references were created beforehand to ensure 
consistency in scoring. In the case of large tissue sections, 
the entirety of the tumor area was evaluated to arrive 
at a consensus score, and images were taken at varying 
magnifications of a field representative of the consensus score.
Brazilian BL TMA
The characteristics of the BL cases were previously 
described [7]. Each individual case was represented by 
3 tumor cores of 0.6 mm diameter, which were obtained 
via biopsy. Cases were scored by staining intensity on a 
scale of 0–3, and the 3 tumor scores for each patient were 
averaged. If the patient only had two or one cores present 
on the slide due to tissue detachment, the cores present were 
used for scoring. The majority of cases were male (74%) 
and under the age of 20 (mean 19.1 years). In each case, the 
original block was classified as BL according to the 2001 
WHO classification. All cases had an immunophenotype 
of CD20+, CD10+ and Ki-67 > 95%. TdT and Bcl-2 were 
negative in all cases. ISH for EBV was positive in 52% 
of cases. In each of these cases, all or virtually all of the 
neoplastic cells stained positive for EBER1. All cases of 
the TMA were studied by FISH using the LSI MYC Dual-
Color Break apart Rearrangement probe.
Eµ-Myc mice
Eµ-Myc mice (n = 51) were obtained from Jackson 
laboratory (strain C57BL/6J-Tg(IghMyc)22Bri/J) and bred 
at UNC-Chapel Hill. All animals were heterozygous for 
the Eµ-Myc transgene. Animals were followed visually 
and palpated every two days. The tumors were excised 
upon necropsy and fixed in 5% formalin/PBS (Fisher 
Diagnostics, Middletown, VA). All animal work was 
conducted according to AAALAC guidelines and was 
approved by the UNC IACUC committee. 
Immunohistochemistry
Formalin-fixed, paraffin embedded BL tumors 
from the University of North Carolina were cut into 7 μm 
thick sections and mounted onto glass slides. Slides were 
dried at 58°C for 3 hours and then placed into a Dako PT 
Link Module (Dako North America Inc, CA, USA) for 
pretreatment at 75°C in 10 mM, pH 6.0 sodium citrate 
buffer, supplemented with 0.05% Tween-20. Buffer 
temperature was raised to 96°C for 25 minutes, and then 
lowered to 75°C. Slides were deparaffinized in room 
temperature diluted wash buffer (Dako North America Inc, 
CA, USA). Endogenous peroxidase activity was blocked 
with 3% hydrogen peroxide. A series of PBS washes was 
done between all subsequent steps. Samples were blocked 
for 30 minutes with 1.5% animal serum from VectaStain™ 
Elite ABC Kits (Vector Laboratories, CA, USA) diluted in 
PBS and supplemented with 1% bovine serum albumin, 
0.1% cold water fish skin gelatin, 0.1% Triton X-100, 
0.05% Tween-20 and 10% Avidin from an Avidin/Biotin 
Blocking Kit (Vector Laboratories, CA, USA). Sections 
were incubated overnight at 4°C in either the antibody 
diluent containing 10% biotin, 1% bovine serum albumin, 
0.1% cold water fish skin gelatin, and 0.1% Triton X-100, 
or a dilution of the primary antibody in the same diluent. 
The appropriate diluted secondary antibody supplemented 
from the respective ABC kit was applied to the sections for 
30 minutes. Sections were incubated in the ABC reagent for 
30 minutes, and then developed with Vector NovaRed™ 
substrate for 5 minutes and counterstained with 0.1% 
Mayer’s Hematoxylin (Electron Microscopy Sciences, PA, 
USA). They were dehydrated and cleared by a series of 
5-minute washes in ethanol and Histochoice™ Clearing 
Agent (Amresco Inc, OH, USA), which was automated 
using a Linear Stainer instrument (Leica, Heidelberg, 
Germany). Slides were mounted using Cytoseal™ 
(Richard-Allan Sci., MI, USA) and glass coverslips. 
Primary antibodies
Ki-67 antibody was used at a 1:100 dilution 
(Thermo Lab Vision, CA, USA), human IgM at 1:400 
(Novocastra Lab Ltd, Newcastle, UK), and CD79a at 
1:100 (Novocastra Lab Ltd, Newcastle, UK). Sections 
were imaged using a Leica DM LA histology microscope 
(Leica, Heidelberg, Germany) equipped with a 20/0.70 
numerical aperture (NA) or a 40/0.75 NA N plan objective 
and Leica DPC480 camera. Images were stored as TIFF 
files under Mac OS X10.8.5. 
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